drugset

drugset / Trial / NCT04637282

Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3

NCT04637282 ↗

Phase 3 Not yet recruiting 39 enrolled Polaryx Therapeutics, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of multiple doses of PLX-200 in patients with CLN3 disease.

Timeline

Start: 2026-11-01
Primary completion: 2026-12-31
Completion: 2026-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gemfibrozil	Small molecule	—	Oral

Indications